R-GNOSIS is coordinated by Marc Bonten (UMC Utrecht) and brings together a multidisciplinary team with complementary expertise of clinicians, microbiologists and epidemiologists, infectious disease specialists, caregivers in inpatient care and mathematical modellers. The R-GNOSIS consortium is made of 19 partners from 9 countries which include United Kingdom, Denmark, Germany, Netherlands, Belgium, France, Spain, Switzerland and Israel.
The Assistance Publique - Hôpitaux de Paris (AP-HP) is the public hospital system of the city of Paris and its suburbs. Providing healthcare, teaching, research, prevention, education and emergency medical service in 52 branches of medicine, it employs more than 90 000 people (practitioners and administrative staff) in 44 hospitals. The APHP is linked with the University of Paris and its seven colleges of medicine, two of odontology and two of pharmacy. It is the largest hospital system in Europe.
Currently managing more than 60 european projects, APHP developed a great experience in managing european projects funded under FP7, including european studies involving APHP as promoter of clinical trials. Since 2009, 2 departments (International promotion and European affairs) work in close collaboration with investigators, researchers and clinical research units to ensure the follow up of clinical trials promoted by APHP when APHP is involved as coordinator or partner in FP7 funded projects.
The scientists in charge of the project, namely Prof Antoine Andremont and Prof Bruno Fantin work as clinicians within hospitals of APHP and the work related to R-GNOSIS will be carried out in the Laboratory of Bacteriology of Bichat Hospital and un the internal medicine wards of Beaujon Hospital, respectively.
The Partner work has been devoted to the role of commensal bacteria in the occurrence of infections in hospitalised patients and to the means to control them. It has developed a special expertise, which is widely recognised both at the national and the international level, on how antibiotic treatments impact the composition of commensal during treatments and on means to control this impact. The laboratory of the partner is fully equipped to assess theses changes both phenotypically on at the molecular lever. It has, over the years, developed reference methods to do so which have been published in recognised journals.
In the project, the Partner will be in charge to receive the faecal samples from the patients involved in the WP3 trial and to assess their microbial composition and bacterial resistance. It will prepare the DNA from theses samples to be transferred to the proposal partners which will be in charge on the genetic studies to be performed on these samples.
Further information: firstname.lastname@example.org; email@example.com
|ANDREMONT Antoine, MD (University of Tours, France, 1976), PhD (University of Paris 11, France, 1986), Board certified in paediatrics, tropical medicine and medical microbiology. Professor of microbiology, University of Paris7 medical School, France. Head, laboratory of Bacteriology, 3BLM University Hospital Paris, France. Head National Reference Center for bacterial resistance in commensal floras. Large experience on the impact of antibiotics on the commensal floras. Expertise in infection control.|
|Bruno Fantin, MD, PhD. Professor of internal medicine. Head of internal medicine at Beaujon hospital. Head of research laboratory on emergence of resistance in vivo at UP7. Focus of interest: relationship between drug exposure and emergence of resistance.|